Aimovig patient assistance application

Disclaimer: These links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Amgen of any of the products, services, or opinions of the organization or individual. Amgen bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.

Simply call 1-833-AIMOVIG (833-246-6844), Monday-Friday, 8:00 am-9:00 pm ET. You’ll receive live support for your questions from knowledgeable representatives.

SUMMARY OF TERMS AND CONDITIONS

It is important that every patient read and understand the full Aimovig ® (erenumab-aooe) Copay Card Terms and Conditions. The following summary is not a substitute for reviewing the Terms and Conditions in their entirety.

As further described in the full terms and conditions, in general:

• The Aimovig ® Copay Card is open to patients with commercial insurance, regardless of financial need. The program is not valid for patients whose Aimovig ® prescription is paid for in whole or in part by Medicare, Medicaid, or any other federal or state programs. It is not valid for cash-paying patients or where prohibited by law.
• With the Aimovig ® Copay Card, a commercially insured patient who meets eligibility criteria may pay as little as a $5 copay per month for their Aimovig ® monthly out-of-pocket costs. Monthly out-of-pocket costs include co-payment, co-insurance, and deductible out-of-pocket costs. Amgen will pay the remaining eligible out-of-pocket costs on behalf of the patient up to a Maximum Monthly Benefit, a Maximum Annual Program Benefit and/or the Patient Total Program Benefit. Patients are responsible for all amounts that exceed these limits.
• The program provides assistance up to a Maximum Monthly Benefit except that the Maximum Monthly Benefit will not apply to the first 2 uses of the Aimovig ® Copay Card for Aimovig ® in any given calendar year.
• Offer is subject to change or discontinuation without notice.
• The Aimovig ® Copay Card provides support up to the Maximum Monthly Benefit, the Maximum Annual Program Benefit and/or Patient Total Program Benefit. If a patient’s commercial insurance plan imposes different or additional requirements on patients who receive Aimovig ® Copay Card benefits, Amgen has the right to reduce or eliminate those benefits. Whether you are eligible to receive the Maximum Monthly Benefit, Maximum Program Benefit or Patient Total Program Benefit is determined by the type of plan coverage you have. Please ask your Aimovig Ally™ representative to help you understand eligibility for the Aimovig ® Copay Card, and whether your particular insurance coverage is likely to result in your reaching the Maximum Monthly Benefit, the Maximum Annual Program Benefit, or your Patient Total Program Benefit, by calling 1-833-AIMOVIG (833-246-6844) .
• Please see the full Terms and Conditions at www.aimovigcopaycard.com/tcs .

MORE TO EXPLORE

Long-term efficacy data with results out to 5 years

Aimovig ® has broad coverage

Aimovig ® pivotal, long-term, and head-to-head safety data

*87% of patients are covered for Aimovig ® based on MMIT data of commercial, Medicare, and Medicaid covered lives. Based on reported coverage as of February 2024. 2 Product coverage is determined by the payer and is subject to change without notice.

INDICATION

Aimovig ® (erenumab-aooe) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

Contraindication: Aimovig ® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig ® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig ® and initiate appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig ® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig ® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.

Monitor patients treated with Aimovig ® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig ® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig ® was discontinued in many of the reported cases.

Monitor patients treated with Aimovig ® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig ® is warranted if evaluation fails to establish an alternative etiology.

Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig ® -treated patients and more often than placebo) were injection site reactions and constipation.